Latest Finance News

Core Lithium has successfully raised $50 million through a two-tranche institutional placement, complemented by a $10 million Share Purchase Plan, to accelerate its Finniss Lithium Project towards a Final Investment Decision.

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

Nickel Industries reported a robust 81% rise in half-year profit to US$25.5 million, while advancing the Excelsior Nickel Cobalt project towards commissioning. The company also declared a final dividend and highlighted sustainability achievements.

Cyprium Metals unveils a rapid restart plan for its Nifty Copper Complex, backed by a substantial A$80 million capital raise to fund early cash flow and long-term growth. The project boasts a pre-tax NPV of A$1.1 billion, positioning Cyprium as a compelling copper play on the ASX.

Solvar Limited reported a robust FY25 with a 17.4% increase in normalised NPAT and launched Bennji, a new commercial lending brand targeting small businesses.

SPC Global Holdings Ltd has reported FY25 proforma results exceeding guidance with a normalised EBITDA of $30.3 million, setting the stage for ambitious growth and international expansion in FY26.

De.mem Limited has reported a record half-year performance for 2025, with revenue up 20% and its first positive adjusted EBITDA, driven by strong recurring revenues and strategic acquisitions.

Resimac Group Ltd delivered a robust FY25 performance, marked by strong organic growth in home loans and asset finance, bolstered by the strategic acquisition of Westpac's $1.5 billion auto portfolio. The company raised dividends to 19 cents fully franked, reflecting confidence amid rising impairment expenses.

Resimac Group reported a 13% rise in operating profit for FY25, driven by strong asset growth and a major auto finance acquisition, while declaring a total dividend of 19 cents per share.

Resimac Group Ltd reported a stable FY25 net profit after tax of $34.6 million and declared a fully franked final dividend of 3.5 cents per share, maintaining its steady financial footing amid modest revenue growth.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.